Company news
Innovent Biologics, Inc. news in 2026
Innovent Biologics, Inc.'s news releases, calls and decks from 2026, newest first.
Voluntary announcement - innovent's partner ollin biosciences and its next-generation medicines for patients with vision-threatening eye diseases to be acquired
November 16, 2026
Voluntary announcement - Zybrivo (sintilimab) receives positive CHMP opinion for first-line treatment of non-squamous non-small cell lung cancer
November 15, 2026
Voluntary announcement - inclusion of seven innovative products including mazdutide and PECONDLE in the 2026 national reimbursement drug list
November 15, 2026
Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List
November 13, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
November 5, 2026
Inside information announcement - product revenue in the third quarter of 2026
October 28, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 7, 2026
2026 Interim report
September 29, 2026
Voluntary announcement - Jaypirca (pirtobrutinib) approved in China for a new indication in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) across all lines of therapy
September 28, 2026
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
September 27, 2026
Altruist Biologics' Suzhou Site Receives EMA GMP Certification, Enabling Product Commercialization for the European Market
September 22, 2026
Innovent Announces 2026 Interim Results and Business Updates
August 25, 2026
Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
August 9, 2026
Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
July 14, 2026
Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
June 30, 2026
Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
June 21, 2026
World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA
June 4, 2026
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
May 31, 2026
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
May 31, 2026
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
May 28, 2026
2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
May 21, 2026
Innovent Announces IBI363 (PD-1/IL-2α-bias Bispecific Fusion Protein) Received Third NMPA Breakthrough Therapy Designation for MSS/pMMR Metastatic Colorectal Cancer
May 10, 2026
Innovent to Present New Clinical Data of IBI363(PD-1/IL-2α-biased bispecific fusion protein) at the 2026 ASCO Annual Meeting
April 21, 2026
Immune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases
April 9, 2026
Altruist Biologics' Hangzhou Facility Secures First Commercial Manufacturing License
April 8, 2026
Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
March 30, 2026
Innovent Announces 2025 Annual Results and Business Updates
March 26, 2026
The Phase 3 Registration STAR Study of Efdamrofusp Alfa (IBI302) Met its Primary Endpoint, Making it the First Self-developed Extended-interval Treatment for nAMD in China
March 23, 2026
Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study
March 22, 2026
Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
March 1, 2026
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer
February 12, 2026
Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology
February 8, 2026
Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma
January 26, 2026
Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
January 8, 2026
Decks in 2026
- H1 2026 Earnings Presentation
Earnings · 55 slides · August 2026